Randomized multicenter open-label phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-positive recurrent platinum-sensitive ovarian cancer

Brief description of study

This study is designed for patients diagnosed with FRa-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers after second line platinum-based chemotherapy plus bevacizumab. The purposes of this study are:

  • To determine if mirvetuximab soravtansine (MIRV) plus BEV is effective at keeping ovarian cancer from relapsing in patients recurrent platinum sensitive ovarian cancer cancer iafter chemotherapy in the maintenance setting (meaning to assess if it helps to prevent their cancer from returning or delaying their cancer’s return).
  • To determine if mirvetuximab soravtansine (MIRV) plus BEV is more effective at managing patients with ovarian cancer and maintenance setting than treatment with BEV alone.
  • To find out what side effects, both good and/or bad, MIRV plus BEV may have on patients with ovarian cancer.
  • To assess if taking MIRV and BEV affects quality of life, both good and/or bad.


    • Clinical Study Identifier: s22-00972


    If you are registered as a volunteer, please log in to contact the study team/express interest in this study.